Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2016 ).
- 15 Jan 2016 Planned End Date changed from 1 Aug 2015 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 15 Jan 2016 Planned primary completion date changed from 1 Aug 2015 to 1 May 2013, according to ClinicalTrials.gov record.